The Food and Drug Administration (FDA) approved the drug Auvelity this week for the treatment of agitation in adults with ...

Auvelity, already on the market for depression, avoids the black box warning carried by the only other approved treatment for ...

Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease May 1, 2026 8:00 ...

The FDA expanded the indication for dextromethorphan hydrobromide and bupropion hydrochloride (Auvelity) extended-release ...

The FDA has approved Auvelity for treating agitation in patients with dementia due to Alzheimer’s disease, Axsome ...

The sub-study examined the impact of the therapy on prespecified Alzheimer’s plasma biomarkers in the subjects. Credit: ...

New research identifies critical ages for Alzheimer's biomarkers, enhancing screening strategies and understanding ...

Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at ...

Researchers at UC San Diego say they recently uncovered new insights into a protein that has emerged as a potential molecular “switch” that may determine whether Alzheimer’s-like brain changes lead to ...

Should you receive a diagnosis of AD, many factors shape how symptoms unfold. The brain, even when under siege, retains an ...

Research reveals why Alzheimer’s brain damage doesn’t always lead to dementia, highlighting the role of protective brain ...

Researchers at the Indiana University School of Medicine have developed a new way to read the brain's "energy network ...